No results for ‘’
Glenmark Pharmaceuticals Ltd
₹2209.60
(1.52%)
Mon, 15 Jun 2026, 06:42 pm
Health Technology
Pharmaceuticals: Major
24.5KGlenmark Pharmaceuticals Shareholding
| Shareholders | MAR 2026 | DEC 2025 | SEPT 2025 | JUN 2025 | MAR 2025 |
|---|---|---|---|---|---|
| Promoters | 46.65 | 46.65 | 46.65 | 46.65 | 46.65 |
| FII | 20.34 | 19.20 | 20.73 | 20.62 | 23.16 |
| DII | 19.29 | 20.09 | 18.61 | 17.64 | 14.60 |
| Public | 13.68 | 14.02 | 13.97 | 15.06 | 15.56 |
| Government | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
Glenmark Pharmaceuticals Ltd Shareholding Pattern
The Glenmark Pharmaceuticals Ltd shareholding pattern provides detailed insights into how ownership of the company is distributed among promoters, FIIs, DIIs, public investors, and government entities. Tracking the Glenmark Pharmaceuticals Ltd shareholding structure helps investors understand institutional confidence, promoter commitment, and overall market sentiment.
Glenmark Pharmaceuticals Ltd (NSE: GLENMARK, BSE: 532296) operates in the Health technology sector and Pharmaceuticals: major industry. Monitoring the Glenmark Pharmaceuticals Ltd shareholding pattern regularly allows investors to analyze ownership trends and make informed investment decisions.
Glenmark Pharmaceuticals Ltd Shareholding Pattern (Latest)
The latest Glenmark Pharmaceuticals Ltd shareholding for Mar 2026 is:
- Promoters: 46.65%
- FII: 20.34%
- DII: 19.29%
- Public: 13.68%
- Government: 0.04%
Promoter holding in Glenmark Pharmaceuticals Ltd has increased, indicating strong confidence from company promoters.
Glenmark Pharmaceuticals Ltd Promoter Holding Trend
Promoter shareholding plays a crucial role in evaluating management confidence in Glenmark Pharmaceuticals Ltd.
- Mar 2026: 46.65%
- Dec 2025: 46.65%
- Sept 2025: 46.65%
- Jun 2025: 46.65%
- Mar 2025: 46.65%
Promoter stake in Glenmark Pharmaceuticals Ltd has increased, indicating strong long-term confidence.
Glenmark Pharmaceuticals Ltd FII Shareholding Trend
Foreign Institutional Investors (FIIs) reflect global investor sentiment toward Glenmark Pharmaceuticals Ltd.
- Mar 2026: 20.34%
- Dec 2025: 19.20%
- Sept 2025: 20.73%
- Jun 2025: 20.62%
- Mar 2025: 23.16%
FII holding in Glenmark Pharmaceuticals Ltd has increased recently, indicating rising foreign investor interest.
Glenmark Pharmaceuticals Ltd DII Shareholding Trend
Domestic Institutional Investors (DIIs) include mutual funds, banks, and insurance companies.
- Mar 2026: 19.29%
- Dec 2025: 20.09%
- Sept 2025: 18.61%
- Jun 2025: 17.64%
- Mar 2025: 14.60%
DII holdings remain stable, reflecting steady institutional participation.
Glenmark Pharmaceuticals Ltd Public Shareholding Trend
Public shareholding represents retail and non-institutional investors.
- Mar 2026: 13.68%
- Dec 2025: 14.02%
- Sept 2025: 13.97%
- Jun 2025: 15.06%
- Mar 2025: 15.56%
Public holding remains stable with consistent retail participation.
Glenmark Pharmaceuticals Ltd Government Holding
Government holding in Glenmark Pharmaceuticals Ltd currently stands at 0.04%.
Government presence indicates institutional backing and regulatory confidence.
Glenmark Pharmaceuticals Ltd Shareholding Analysis Summary
The Glenmark Pharmaceuticals Ltd shareholding pattern highlights the ownership structure and investor confidence in the company. Stable promoter holdings combined with institutional participation often indicate strong fundamentals and long-term growth potential.
Investors should monitor changes in Glenmark Pharmaceuticals Ltd shareholding for signals on institutional sentiment and ownership trends.
Regular monitoring of the Glenmark Pharmaceuticals Ltd shareholding helps investors understand market confidence, institutional activity, and potential future stock movements.